The 21-gene recurrence score (RS), which quantifies the likelihood of distant recurrence in tamoxifen-treated patients with estrogen receptor (ER)-positive breast cancer, was initially developed as a prognostic marker [1]. The gene discussed is ESR1; the disease is breast cancer.